Drug Profile
INXN 2001
Alternative Names: Ad-IL-12; Ad-RTS-hIL-12; Ad-RTS-hIL-12 plus veledimex; Ad-RTS-IL-12; Ad-RTS-mIL-12; Adenoviral-vector-interleukin-12-gene-therapy-Alaunos Therapeutics; Controlled IL-12; INXN2001; ZIN-ATI-001Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator
- Developer Alaunos Therapeutics; ZIOPHARM Oncology
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; Interleukin-12 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer; Glioblastoma
- Phase I/II Diffuse intrinsic pontine glioma
- Suspended Malignant melanoma
- No development reported Glioma
- Discontinued Colorectal cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Glioblastoma(Monotherapy, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Injection)
- 03 Apr 2023 Precigen regains its erxclusive rights from Alaunos Therapeutics
- 26 Jan 2022 ZIOPHARM Oncology is now called Alaunos Therapeutics